Riptide peptide turns TAMs proinflammatory
Riptide unveils preclinical pancreatic cancer data, shows candidate reprograms TAMs
Riptide has lifted the curtain on its first immuno-oncology program, RP-182, which comprises an engineered peptide that reprograms tumor-associated macrophages to become proinflammatory.
Strategies to convert immunosuppressive macrophages into proinflammatory cells have been gaining momentum as a way to simultaneously
